30-05-2020 | ASCO 2020 | Conference coverage | Video
Researcher comment: Introducing a phase 1 trial of ladiratuzumab vedotin
Jame Abraham describes the design of a phase 1 trial now investigating the novel LIV-1-targeted antibody–drug ladiratuzumab vedotin in patients with metastatic breast cancer (3:43).